Logo
x

Search

Subscribe Now

Immuno-oncology

Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M

Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M

  • April 27, 2021
BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration

BMS and PsiOxus Therapeutics Expand their 2016 Immuno-Oncology Collaboration

  • April 8, 2021
Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star

Merck KGaA Exercises Third Option in its Immuno-Oncology Collaboration with F- star

  • April 5, 2021
Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology

Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology

  • February 16, 2021
Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star

Merck KGaA Takes an Early Option in its Existing Immuno-Oncology Collaboration with F-star

  • July 17, 2020
GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

  • December 31, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.